Fig. 4

Analyses of mononuclear cells from patients with and without hepatitis C before and after IFN-α treatment. (A) Immunoblot analyses of extracts of blood mononuclear cells from hepatitis C patients before and after IFN-α treatment. Equivalent amounts of cellular protein were analyzed in each lane. Antibody 1E8-B8 was used. Samples from patients 1 to 4 were collected before IFN-α treatment (pre-IFN-α) or after receiving IFN-α in vivo (post-IFN-α). Controls for human NOS2 were from the human colon cancer cell line DLD-1 without (−) or with (+) treatment with IFN-γ, IL-1, and TNF in vitro. (B) Reverse transcriptase-polymerase chain reaction analysis of mononuclear cells from normal subjects, patients with hepatitis C, and patients with hepatitis C treated in vivo with IFN-α. Cells were isolated, frozen, extracted, and analyzed as noted in Materials and Methods. Cells from the two normal subjects (HEP C− and IFN-α−), one patient with hepatitis C (HEP C+ and IFN-α−), and two patients with hepatitis C on treatment with IFN-α (HEP C + and IFN-α+) were analyzed. M, molecular weight markers; D, cells of the human colon cancer cell line DLD-1 treated with IFN-γ, IL-1, and TNF; W, distilled water. [Reproduced with permission (76).]